COVID treatment: Henry Ford Health works to increase access to monoclonal antibody therapy
Published:
Tags:
A laboratory worker at Eli Lilly prepares a solution used to manufacture bamlanivimab, a new monoclonal antibody therapy for COVID-19. When given within 10 days of a positive COVID-19 test, these man-made antibodies may help lessen the severity of the disease and reduce the need for hospitalization in people most at risk of developing severe COVID-19. (Provided by UF Health)
Henry Ford Health System announced Thursday, in partnership with the U.S. Department of Health and Human Services (HHS), that it is boosting access to monoclonal antibody therapy in southeast Michigan.